share_log

Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $29

Benzinga ·  Jan 3 10:12

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and raises the price target from $28 to $29.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment